von Willebrand disease: proposing definitions for future research.
作者信息
Connell Nathan T, James Paula D, Brignardello-Petersen Romina, Abdul-Kadir Rezan, Ameer Barbara, Arapshian Alice, Couper Susie, Di Paola Jorge, Eikenboom Jeroen, Giraud Nicolas, Grow Jean M, Haberichter Sandra, Jacobs-Pratt Vicki, Konkle Barbara A, Kouides Peter, Laffan Michael, Lavin Michelle, Leebeek Frank W G, McLintock Claire, McRae Simon, Montgomery Robert, O'Brien Sarah H, O'Donnell James S, Ozelo Margareth C, Scappe Nikole, Sidonio Robert, Tosetto Alberto, Weyand Angela C, Kalot Mohamad A, Husainat Nedaa, Mustafa Reem A, Flood Veronica H
机构信息
Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Department of Medicine, Queen's University, Kingston, ON, Canada.
出版信息
Blood Adv. 2021 Jan 26;5(2):565-569. doi: 10.1182/bloodadvances.2020003620.
Abstract
摘要
相似文献
1
von Willebrand disease: proposing definitions for future research.血管性血友病：为未来研究提出定义。
Blood Adv. 2021 Jan 26;5(2):565-569. doi: 10.1182/bloodadvances.2020003620.
2
Biology of inherited coagulopathies: von Willebrand factor.遗传性凝血障碍的生物学：血管性血友病因子
Hematol Oncol Clin North Am. 1992 Oct;6(5):1011-20.
3
Diagnosis and incidence of inherited von Willebrand disease.遗传性血管性血友病的诊断与发病率
Curr Opin Hematol. 2001 Sep;8(5):306-11. doi: 10.1097/00062752-200109000-00007.
4
Current approaches to pregnancy and childbirth in women with von Willebrand disease.血管性血友病女性妊娠和分娩的当前处理方法。
Clin Adv Hematol Oncol. 2018 Apr;16(4):254-257.
5
von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M.2A、2B和2M型血管性血友病中血管性血友病因子胶原结合试验
J Thromb Haemost. 2006 Sep;4(9):2088-90. doi: 10.1111/j.1538-7836.2006.02069.x.
6
Slippery criteria for von Willebrand disease type 1.1型血管性血友病的模糊诊断标准。
J Thromb Haemost. 2004 Oct;2(10):1720-3. doi: 10.1111/j.1538-7836.2004.00933.x.
7
The spectrum of mutations in Southern Spanish patients with von Willebrand disease.西班牙南部血管性血友病患者的突变谱。
Haemophilia. 2015 May;21(3):e240-e242. doi: 10.1111/hae.12649. Epub 2015 Feb 17.
8
Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease.1型隐匿性血管性血友病患者的多种血管性血友病因子突变
Thromb Res. 2007;120(3):451-3. doi: 10.1016/j.thromres.2006.10.017. Epub 2006 Dec 15.
9
[Inborn and acquired von Willebrand disease].[先天性和获得性血管性血友病]
Hamostaseologie. 2008 Dec;28(5):312-9.
10
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).欧洲研究中血管性血友病患者的血管性血友病因子多聚体详细分析，1型血管性血友病（MCMDM-1VWD）诊断和管理的分子及临床标志物
J Thromb Haemost. 2008 May;6(5):762-71. doi: 10.1111/j.1538-7836.2008.02945.x. Epub 2008 Mar 1.
引用本文的文献
1
Prevalence of heavy menstrual bleeding, iron deficiency, iron deficiency anemia, and treatment in women with von Willebrand disease-a cohort study.血管性血友病女性中月经过多、缺铁、缺铁性贫血的患病率及治疗——一项队列研究
Res Pract Thromb Haemost. 2025 Jun 20;9(4):102949. doi: 10.1016/j.rpth.2025.102949. eCollection 2025 May.
2
A 4-Week-Old Female Infant with Type 3 von Willebrand Disease Presenting with Nosebleeds and Uncontrolled Bleeding Following Surgical Frenectomy: A Clinical Case.一名4周大的患有3型血管性血友病的女婴，出现鼻出血以及舌系带切除术术后出血不止：一例临床病例
Am J Case Rep. 2025 May 26;26:e946625. doi: 10.12659/AJCR.946625.
3
Von Willebrand disease (VWD) and pregnancy: a comprehensive overview.血管性血友病（VWD）与妊娠：全面概述
Thromb J. 2025 Apr 28;23(1):41. doi: 10.1186/s12959-025-00727-7.
4
2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease.2025年美国血液学会（ASH）、国际血栓与止血学会（ISTH）、世界血友病联盟（WFH）关于2021年血管性血友病诊断与管理临床指南的监测报告。
Blood Adv. 2025 Jul 22;9(14):3553-3555. doi: 10.1182/bloodadvances.2025016512.
5
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study.血管性血友病女性患者诊断延迟及失访的预测因素：一项单中心回顾性队列研究
Res Pract Thromb Haemost. 2024 Sep 12;8(6):102567. doi: 10.1016/j.rpth.2024.102567. eCollection 2024 Aug.
6
Epidemiological, Demographic, and Clinical Characteristics of Von Willebrand Disease Patients in Zahedan City, Iran: A Descriptive Study.伊朗扎黑丹市血管性血友病患者的流行病学、人口统计学和临床特征：一项描述性研究
Int J Hematol Oncol Stem Cell Res. 2024 Jul 1;18(3):220-226. doi: 10.18502/ijhoscr.v18i3.16102.
7
von Willebrand disease.血管性血友病。
Nat Rev Dis Primers. 2024 Jul 25;10(1):51. doi: 10.1038/s41572-024-00536-8.
8
Tranexamic acid for management of heavy vaginal bleeding: barriers to access and myths surrounding its use.氨甲环酸用于治疗严重阴道出血：获取药物的障碍及围绕其使用的误解
Res Pract Thromb Haemost. 2024 Mar 19;8(3):102389. doi: 10.1016/j.rpth.2024.102389. eCollection 2024 Mar.
9
Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies.再次探讨 1 型血管性血友病的分类：来自 LoVIC 和 WiN 研究联合分析的新见解。
Blood. 2024 Apr 4;143(14):1414-1424. doi: 10.1182/blood.2023022457.
10
Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review.去氨加压素治疗血管性血友病患者：一项系统评价
Cureus. 2023 Aug 29;15(8):e44310. doi: 10.7759/cureus.44310. eCollection 2023 Aug.
本文引用的文献
1
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.ASH ISTH NHF 2021 指南：关于血管性血友病的诊断。
Blood Adv. 2021 Jan 12;5(1):280-300. doi: 10.1182/bloodadvances.2020003265.
2
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.美国血液学会（ASH）、国际血栓与止血学会（ISTH）、美国国家血友病基金会（NHF）、世界血友病联盟（WFH）2021年血管性血友病管理指南
Blood Adv. 2021 Jan 12;5(1):301-325. doi: 10.1182/bloodadvances.2020003264.
3
Desmopressin responsiveness by age in type 1 von Willebrand disease.1型血管性血友病中去氨加压素反应性随年龄的变化
Res Pract Thromb Haemost. 2020 May 30;4(6):1046-1052. doi: 10.1002/rth2.12354. eCollection 2020 Aug.
4
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.一项比较二级长期预防与按需使用 vWF/FVIII 浓缩物治疗严重遗传性血管性血友病的 III 期研究。
Blood Transfus. 2019 Sep;17(5):391-398. doi: 10.2450/2019.0183-18. Epub 2019 Feb 4.
5
Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.接受择期手术的重型血管性血友病患者中重组血管性血友病因子的 3 期研究。
J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.
6
Desmopressin in moderate hemophilia A patients: a treatment worth considering.中重度血友病 A 患者使用去氨加压素治疗：一种值得考虑的治疗方法。
Haematologica. 2018 Mar;103(3):550-557. doi: 10.3324/haematol.2017.180059. Epub 2018 Jan 5.
7
Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.对低血管性血友病因子（VWF）水平潜在的临床表型和病理生理学的新见解。
Blood. 2017 Nov 23;130(21):2344-2353. doi: 10.1182/blood-2017-05-786699. Epub 2017 Sep 15.
8
Efficacy and safety of a VWF/FVIII concentrate (wilate ) in inherited von Willebrand disease patients undergoing surgical procedures.一种血管性血友病因子/凝血因子VIII浓缩物（威尔特）在接受外科手术的遗传性血管性血友病患者中的疗效和安全性。
Haemophilia. 2017 Mar;23(2):264-272. doi: 10.1111/hae.13106. Epub 2016 Dec 27.
9
Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.去氨加压素在接受侵入性操作的血管性血友病患者中应用的实践情况：一项欧洲调查
Haemophilia. 2016 Jan;22(1):110-20. doi: 10.1111/hae.12763. Epub 2015 Jul 24.
10
Measurement of blood loss during postpartum haemorrhage.产后出血期间失血量的测量。
Int J Obstet Anesth. 2015 Feb;24(1):8-14. doi: 10.1016/j.ijoa.2014.07.009. Epub 2014 Jul 27.
Zotero 插件